A European study published this week finds that, at a minimum of 3.3 years after market entry, there was no conclusive evidence that many oncology drugs approved by the European Medicines Agency between 2009 and 2013 either extended or improved life in most oncology indications.
Available US data show that only a small proportion of FDA-approved cancer treatments unequivocally benefit survival or quality of life (QOL). Now a European study published in BMJ finds that, at a minimum of 3.3 years after market entry, there was no conclusive evidence that many oncology drugs approved by the European Medicines Agency (EMA) between 2009 and 2013 either extended or improved life in most oncology indications, and although there were demonstrated survival gains over existing treatment options or placebo, they were often marginal. Study author Courtney Davis, PhD, and colleagues also note that most drugs entered the European market without evidence of benefit on survival or QOL.
The retrospective cohort study was based on publicly accessible regulatory and scientific reports on EMA cancer drug approvals from 2009 to 2013, a period during which 48 cancer drugs were approved for 68 indications. The study excluded pediatric indications and indications for the treatment of benign tumors. Supportive treatments and generic products were not considered. The study limited scoring on the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) to drugs for solid tumors because the scale is not intended to be used to evaluate drugs that treat hematological malignancies.
Of the 68 indications studied, 12% were approved on the basis of a single-arm study. Thirty-three indications were first marketing authorizations and 35 were extensions. Overall, 72 clinical trials supported the approval of the 68 novel drug uses.
The authors found that only 26% of approved indications were supported by a pivotal study powered to evaluate overall survival (OS) as the primary outcome. None of the 10 conditionally authorized uses evaluated survival as the primary endpoint, and OS was evaluated as a primary study endpoint in only 31% of all drug indications that were granted regular marketing authorizations. Remaining drug indications were supported by trials evaluating a surrogate measure as the primary study outcome, and none of the pivotal trials assessed QOL as a primary endpoint.
The study found that at the time of marketing approval:
After a median of 5.4 years of follow-up (range, 3.3 to 8.1):
Although the goal of cancer treatment is to improve both the quantity and the quality of life, clinical trials designed to gain regulatory approval for new drugs often evaluate indirect or surrogate measures of drug efficacy, the authors say. “These endpoints show that an agent has biological activity, but they are not reliable surrogates for improved survival or [QOL] in all settings.” Recent systematic reviews suggest that the strength of association between surrogates in cancer clinical trials and life extension is generally low, the authors note, and it is concerning that many new, increasingly expensive cancer treatments, often promoted as breakthroughs, have marginal benefits that might not be clinically meaningful to patients.
“Most new oncology drugs authorized by the EMA from [2009 to 2013] came onto the market without clear evidence that they improved the quality or quantity of patients’ lives, and, when survival gains over available treatment alternatives were shown, they were not always clinically meaningful,” the authors conclude. Finally, they caution that little new information to guide patients or clinicians was generated in the post-marketing period studied—a situation with negative implications for both patients and public health.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.